PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2)

• Silvana Novelli,
• Ashish Risal,
• Manjusha Namuduri,
• Jingxian Cai,
• Melanie Ufkin,
• Min Zhu,
• Sushmita Mukherjee,
• Jurriaan Brouwer-Visser,
• Aafia Chaudhry,
• Hesham Mohamed,
• Srikanth Ambati,
• Elżbieta Iskierka-Jażdżewska

Affiliations

Silvana Novelli

1 Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Ashish Risal

2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States

Manjusha Namuduri

2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States

Jingxian Cai

2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States

Melanie Ufkin

2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States

Min Zhu

2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States

Sushmita Mukherjee

2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States

Jurriaan Brouwer-Visser

2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States

Aafia Chaudhry

2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States

Hesham Mohamed

2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States

Srikanth Ambati

2 Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, United States

Elżbieta Iskierka-Jażdżewska

3 Copernicus Memorial Hospital, Department of General Hematology, Medical University of Łódź, Łódź, Poland